Retinal Neurovascular Coupling in Patients Previously Infected With COVID-19

Last updated: May 13, 2025
Sponsor: Medical University of Vienna
Overall Status: Active - Recruiting

Phase

N/A

Condition

Covid-19

Treatment

Dynamic Vessel Analyzer (DVA)

Fourier domain optical coherence tomography (FDOCT)

Laser Speckle Flowgraphy (LSFG)

Clinical Study ID

NCT05650905
OPHT-180520
  • Ages > 18
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

The Study objective is to measure retinal neurovascular coupling and blood flow parameters in patients previously infected with COVID-19, long COVID-19 and healthy age- and sex- matched control subjects

Eligibility Criteria

Inclusion

Inclusion Criteria:

Inclusion criteria for healthy subjects

  • Men and women aged over 18 years

  • Non-smokers

  • Normal findings in the medical history unless the investigator considers anabnormality to be clinically irrelevant

  • No previous history of COVID-19 infection

  • Negative testing for SARS-CoV-2 seroprevalence using nucleocapsid antibody tests

  • Negative PCR test for SARS-CoV-2

  • Normal ophthalmic findings, ametropy < 6 Dpt.

Inclusion criteria for subjects with history of COVID-19 infection

  • Men and women aged over 18 years

  • Non-smokers

  • History of COVID-19 infection (confirmed by a positive PCR test for SARS-CoV2 in themedical history) within the last 6 months

  • Positive testing for SARS-CoV-2 seroprevalence using spike protein IgG antibodytests

  • Negative PCR test for SARS-CoV-2

Inclusion criteria for subjects with long COVID-19

  • Men and women aged over 18 years

  • Non-smokers

  • History of COVID-19 infection (confirmed by a positive PCR test for SARS-CoV2 in themedical history)

  • Positive testing for SARS-CoV-2 seroprevalence

  • Negative PCR test for SARS-CoV-2

  • Long Covid according to the latest WHO-Guidelines

Exclusion

Exclusion Criteria:

Any of the following will exclude a healthy control subject from the study:

  • Symptoms of a clinically relevant illness in the 3 weeks before the first study day

  • Presence or history of a severe medical condition as judged by the clinicalinvestigator

  • Participation in a clinical trial in the 3 weeks preceding the study

  • Blood donation during the previous three weeks

  • History or family history of epilepsy

  • Presence of any abnormalities preventing reliable measurements in the study eye asjudged by the investigator

  • Best corrected visual acuity < 0.8 Snellen

  • Pregnancy, planned pregnancy or lactatin

  • History of epilepsia

Any of the following will exclude a subject with history of COVID-19 infection from the study:

  • Blood donation during the previous three weeks

  • History or family history of epilepsy

  • Presence of any abnormalities preventing reliable measurements in the study eye asjudged by the investigator

  • Best corrected visual acuity < 0.8 Snellen

  • Ametropy >6 Dpt

  • Pregnancy, planned pregnancy or lactating

  • History of epilepsia

Any of the following will exclude a subject with long COVID-19 from the study:

  • Blood donation during the previous three weeks

  • History or family history of epilepsy

  • Presence of any abnormalities preventing reliable measurements in the study eye asjudged by the investigator

  • Best corrected visual acuity < 0.8 Snellen

  • Ametropy >6 Dpt

  • Pregnancy, planned pregnancy or lactating

  • History of epilepsia

  • Diabetes mellitus

Study Design

Total Participants: 90
Treatment Group(s): 5
Primary Treatment: Dynamic Vessel Analyzer (DVA)
Phase:
Study Start date:
July 26, 2021
Estimated Completion Date:
December 31, 2025

Study Description

The coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is affecting almost all countries in the world and because of its worldwide spread has been declared as pandemic in March 2020. While respiratory symptoms are the main manifestation of acute infection, there is also increasing evidence that neurological and vascular symptoms occur, and it is unknown whether residuals remain after patients have recovered. A recent report shows that changes in the human retina are even present one month after onset of symptoms. The eye, as an extension of the brain, offers the advantage that blood vessels as well as neural tissue can be visualized non-invasively in-vivo. Neurovascular coupling is the ability of neural tissue to adapt its blood flow to its metabolic demands, a phenomenon that does not only occur in the brain, but also in the retina. In the retina, neurovascular coupling can be studied by stimulating the retina with flicker light and measuring the response of the vessels. Retinal neurovascular coupling has been found to be impaired in diseases of the central nervous system (CNS) as well as in diseases associated with endothelial dysfunction. Since COVID-19 comes with CNS manifestations as well as endothelial dysfunction, we speculate that retinal neurovascular coupling might be impaired in patients even after they have recovered from COVID-19 infection. In the current study, retinal neurovascular coupling will be measured in patients who have recovered from COVID-19 infection with and without long COVID-19 and in healthy age- and sex-matched controls with no history of COVID-19 infection. In addition, retinal oxygen saturation, vessel diameters, vessel density as well as retinal and optic nerve head blood flow will be measured. To assess structural changes, measurement of central retinal thickness as well as retinal nerve fiber layer thickness will be performed.

Connect with a study center

  • Medical University of Vienna, Department of Clinical Pharmacology

    Vienna, 1090
    Austria

    Active - Recruiting

+−

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.